Scientific Agenda

Friday, 9 March, 2012

08:15
Welcome and introduction
Pieter E. Postmus, MD, PhD (Amsterdam, the Netherlands)

Session I: Early detection strategies and early stage diagnosis
Moderators: Egbert F. Smit, MD, PhD, VU University Medical Center, Amsterdam, the Netherlands and Silvia Novello, MD, PhD (Torino, Italy)

08:30
Early detection with low-dose CT: an update on recent presented data
John Field, PhD, FRCPath (Liverpool, UK)

08:50
Debate: Which treatment for screening detected tumors?

The surgical approach
Marinus A. Paul, MD, PhD (The Netherlands)

Vs.

The radiotherapeutic approach
Suresh Senan, MD, PhD (Amsterdam, the Netherlands)

09:20
Pet scan in early detection and staging
Christophe Dooms, MD, PhD

09:40
Mediastinal staging: EBUS
Stefano Gasparini, MD, Azienda Ospedali Riuniti, Ancona, Italy

10:00
Mediastinal staging: Mediastinoscopy
Marinus A. Paul, MD, PhD (The Netherlands)

10:20
Break

Session II: Molecular diagnosis in lung cancer
Moderators: Christian Manegold, MD (Heidelberg, Germany) and
Giorgio V. Scagliotti, MD, PhD (Torino, Italy)

10:40
Systematic search for rare mutation in lung adenocarcinoma
Federico Cappuzzo (Livorno, Italy)

11:20
Genetic changes in squamous cell carcinoma
Martin Sos (Cologne, Germany)

11:40
Treatment of EGFR mutant tumors in front- and second-line treatment
Martin Reck, MD, PhD Hospital Grosshansdorf, Grosshansdorf, Germany

12:00
EML4-ALK translocation and crizotinib
Lucio Crinò, MD (Perugia, Italy)

12:20
Detection of mutations in serum
Rafael Rosell, MD (Barcelona, Spain)

12:45
Session II adjourns

13:05
Luncheon satellite symposium
Recent Progress in the Management of Advanced NSCLC
Supported by Eli Lilly and Company

14:35
Luncheon satellite symposium adjourns

Session III: Prognosis, staging, and treatment
Moderators: Pieter E. Postmus, MD, PhD (Amsterdam, the Netherlands) and Silvia Novello, MD, PhD (Torino, Italy)

14:50
Role of the respiratory physician in the diagnosis and treatment of lung cancer
Pieter E. Postmus, MD, PhD (Amsterdam, the Netherlands)

15:10
Impact and application of the IASLC staging project
Paul Van Schil, MD, PhD, Antwer University Hospitalp, Antwerp, Belgium

15:30
Prognostic factors in early stage NSCLC
Giorgio V. Scagliotti, MD, PhD (Torino, Italy)

15:50
Systemic therapy in early stage NSCLC
Christian Manegold, MD (Heidelberg, Germany)

16:10
Targeted therapies in the adjuvant setting
Pieter E. Postmus, MD, PhD (Amsterdam, the Netherlands)

16:30
Break

Session IV: New agents in lung cancer I
Moderators: Christophe Dooms, MD, PhD and Luis Paz-Ares, MD, PhD, Seville University Hospital, Seville, Spain

17:00
Irreversible EGFR TKIs
Luis Paz-Ares, MD, PhD, Seville University Hospital, Seville, Spain

17:20
c-Met inhibitors
David Spigel, MD (Sarah Cannon Research Institute, Nashville, TN, United States)

17:40
PARP inhibition
Silvia Novello, MD, PhD (Torino, Italy)

18:00
Vaccines as adjuvant treatment
Christophe Dooms, MD, PhD

18:20
Wrap up of Day 1

18:30
Adjourn

Saturday, 10 March, 2012

08:00
Welcome and introduction
Giorgio V. Scagliotti, MD, PhD (Torino, Italy)

Session V: Radiotherapy in lung cancer
Moderators: Pieter E. Postmus, MD, PhD (Amsterdam, the Netherlands) and Suresh Senan, MD, PhD (Amsterdam, the Netherlands)

08:10
Stereotactic radiotherapy in early NSCLC and metastases
Suresh Senan, MD, PhD (Amsterdam, the Netherlands)

08:30
Optimizing the dose and schedule of radiation therapy in stage III NSCLC
Umberto Ricardi, MD, PhD (Torino, Italy)

08:50
Integration of targeted agents into combined modality therapy for NSCLC
Corey Langer, MD, FACP, University of Pennsylvania, Philadelphia, Pennsylvania, United States

09:10
Palliative radiotherapy
Dirk de Ruysscher, MD, PhD (Maastricht, the Netherlands)

09:30
Clinical case on combined modality and toxicity
Suresh Senan, MD, PhD (Amsterdam, the Netherlands)

09:50
Break

Session VI: Changing the treatment paradigms in front-line metastatic NSCLC
Moderators: Pieter E. Postmus, MD, PhD (Amsterdam, the Netherlands) and Giorgio V. Scagliotti, MD, PhD (Torino, Italy)

10:20
The role of the pathologist in the therapeutic decision-making process
Keith Kerr, MD (Aberdeen, Scotland)

10:40
The choice of front-line treatment in non-oncogene addicted NSCLC
Silvia Novello, MD, PhD (Torino, Italy)

11:00
Anti-angiogenic agents: Where are we? Which biomarker?
Martin Reck, MD, PhD, Hospital Grosshansdorf, Grosshansdorf, Germany

11:20
Maintenance chemotherapy: A treatment opportunity or a new standard of care?
Luis Paz-Ares, MD, PhD, Seville University Hospital, Seville, Spain

11:40
Second-line and beyond: Which standards?
Egbert F. Smit, MD, PhD, VU University Medical Center, Amsterdam, the Netherlands

12:05
Session VI adjourns

12:25
Luncheon satellite symposium
Through the looking glass: focus on treatment decisions in NSCLC therapy
Supported by F. Hoffmann-La Roche Ltd.

13:55
Luncheon satellite symposium adjourns

Session VII: New agents in lung cancer II
Moderators: Martin Reck, MD, PhD, Hospital Grosshansdorf, Grosshansdorf, Germany and Lucio Crinò, MD (Perugia, Italy)

14:10
Inhibition of Ras-Raf-MEK pathway
Egbert F. Smit, MD, PhD, VU University Medical Center, Amsterdam, the Netherlands

14:30
The PI3K/AKT axis
Lucio Crinò, MD (Perugia, Italy)

14:50
HSP-90 inhibition as an emerging target
Luis Paz-Ares, MD, PhD, Seville University Hospital, Seville, Spain

15:10
Denosumab in lung cancer
Peter G. Harper, MD (London, United Kingdom)

Session VIII: Mesothelioma and special populations
Moderators: Pieter E. Postmus, MD, PhD (Amsterdam, the Netherlands) and Egbert F. Smit, MD, PhD, VU University Medical Center, Amsterdam, the Netherlands

15:30
Elderly patients
Giorgio V. Scagliotti, MD, PhD (Torino, Italy)

15:50
PS2 patients
Corey Langer, MD, FACP, University of Pennsylvania, Philadelphia, Pennsylvania, United States

16:10
Treatment of mesothelioma
Paul Baas MD, PhD, NKI, Amsterdam, the Netherlands

16:30
Adjourn

Audience Participation... A Hands-On Experience

During the scientific sessions, speakers and the audience can exchange information through a “hands-on” computerized speaker-audience interaction system. With this state-of-the-art equipment, participants answer multiple choice questions, and within seconds, the answers are calculated and projected on a screen in tabular or graphic form for all to see. This system maximizes the ability for attendees from diverse disciplines to see differing opinions and compare consensus between the speakers and each other.

 

 

 

©2012 Imedex®, LLC. All rights reserved. Reproduction in whole or part is prohibited without prior written consent from Imedex and contributing faculty.